9-ING-41 + Carboplatin for Salivary Gland Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called 9-ING-41 for patients with advanced salivary gland cancers that don't respond to usual treatments. The new drug aims to slow down the cancer by blocking a specific function that helps cancer cells grow.
Who Is on the Research Team?
Glenn J. Hanna, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
Adults with advanced salivary gland cancer, including adenoid cystic carcinoma, who have not responded to previous treatments or whose disease has returned. They must be in relatively good health with proper organ and bone marrow function, able to provide tissue samples, and willing to use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 9-ING-41 and carboplatin chemotherapy every 21 days for up to 1 year
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may continue treatment beyond 1 year if showing benefit
What Are the Treatments Tested in This Trial?
Interventions
- 9-ING-41
- Carboplatin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Glenn J. Hanna
Lead Sponsor
Actuate Therapeutics Inc.
Industry Sponsor